Market Research Industry Reports

Global Conjunctivitis Drugs Market 2018-2024

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Global Bacterial Conjunctivitis Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Overview:
Bacterial conjunctivitis is a contagious eye infection in which the conjunctiva of one or both the eyes are infected by bacteria such as Staphylococci, Gonococci, Chlamydia, and Streptococci. The infection caused by Chlamydia trachomatis and Neisseria gonorrhea species are extremely severe. However, there are many antibiotics that help in curing these conditions, thus ensuring quicker clearance of the indications of infection. Healio reported that nearly 5 million bacterial conjunctivitis cases are registered every year. There are many antibiotics currently used for the treatment, which include Besivance, Zymaxid, Maxitrol, and AzaSite. These antibiotics can be administered via oral, transdermal, and otic.

Although, most of the bacterial conjunctivitis are self-limiting, yet topical antibiotics are suggested to cut the duration of the disease and avoid the spreading of infection. A wide range of antibiotics are generally used as a primary treatment option for bacterial conjunctivitis. Topical antibiotics are suggested to deliver the highest dose of the drug straight to the infection site, more than what is usually achieved by oral and other routes. Consequently, the broad spectrum of antibiotic of a single drug is improved.

Market Analysis:
The “Global Bacterial Conjunctivitis Drugs Market” is estimated to witness a CAGR of 2.1% during the forecast period 2018–2024. The bacterial conjunctivitis drugs market is analyzed based on two segments – drug class and regions.

Regional Analysis:
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the bacterial conjunctivitis market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by North America, with the US being the major contributor to the market growth.

Drug Class Analysis:
Based on drug classes, the market is segmented into fluoroquinolones, aminoglycosides, macrolides, and others. Fluoroquinolones have a dominant market share for bacterial conjunctivitis. However, this drug class is likely to reduce its market share by 7.2% by the end of 2024 due to weak research pipeline. The highest growth rate is witnessed by aminoglycosides, followed by macrolides. However, the loss of patent of blockbuster drugs, such as Moxeza, Besivance, Vigamox, and Zymaxid, has hampered the growth of the market.

Key Players:
The major players in the market include Novartis, Valeant Pharmaceuticals International, Teva Pharmaceuticals, and Akron Inc. Perrigo Corporation, Bayer AG, Pfizer, Daiichi Sankyo Inc., Merck & Co., and F. Hoffmann-La Roche are few of the prominent drugs manufacturers in the market.

Competitive Analysis:
Many blockbuster drugs are likely to lose their patents in the market, which in turn, has increased the advent of generic drugs with similar efficacy and less cost. Novartis AG is one of the global leaders in the bacterial conjunctivitis market. Vigamox and Moxeza are the key products of the company, which are expected to lose their patents by 2020. This patent expiry is expected to show a negative impact on the company revenue and its market position. Other strategies used by the market players are acquisitions. For instance, in 2015, Shire Plc acquired Foresight Biotherapeutics for a value of $300 million. This acquisition added experimental eye drop FST-100 into the Shire Plc’s portfolio to treat both viral and bacterial conjunctivitis.

Benefits:
The report provides complete details about the usage and adoption rate of bacterial conjunctivitis drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

1 Industry Outlook 8
1.1 Industry Overview 8
1.1.1 Global Driver for Pharmaceutical Demand: 9
1.1.2 Pharmaceutical spending region wise 9
1.1.3 R&D pipeline in pharmaceutical industry 9
1.1.4 Top pharma drugs by sales in 2017 ($Million) 11
1.2 Industry Trends 12
1.3 Total Addressable Market 13
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 15
2.3 Research Methodology 16
2.4 Report Assumptions 16
3 Market Snapshot 18
3.1 Market Definition – Infoholic Research 18
3.2 Segmented Addressable Market (SAM) 18
3.3 Trends of Bacterial Conjunctivitis Drugs Market 19
3.4 Related Markets 20
3.4.1 Contact lenses 20
3.4.1.1 Trends of Contact Lens Market 21
3.4.2 Oncology (Cancer) Drugs 21
3.4.3 Active pharmaceutical ingredients (APIs) 22
3.4.4 Over the counter drugs (OTC) 22
4 Market Outline 23
4.1 Market Segmentation 23
4.2 Porter 5(Five) Forces 24
4.3 PEST Analysis 25
5 Market Characteristics 26
5.1 Market Dynamics of Bacterial Conjunctivitis Drugs Market 26
5.1.1 Drivers 27
5.1.1.1 Increasing awareness among patient population about pink eye disease 27
5.1.1.2 Rising prevalence of bacterial conjunctivitis 27
5.1.2 Opportunities 27
5.1.2.1 Increasing clinical trials 27
5.1.3 Restraints 28
5.1.3.1 Expiry of patents for blockbuster drugs 28
5.1.3.2 Complex drug development process 28
5.1.4 DRO – Impact Analysis 29
5.1.5 Key Stakeholders 29
6 Application: Market Size and Analysis 31
6.1 Overview 31
6.2 Fluoroquinolones 32
6.3 Aminoglycosides 33
6.4 Macrolides 34
6.5 Others 35
7 Regions: Market Size and Analysis 37
7.1 Overview 37
7.2 North America 38
7.2.1 Overview 38
7.3 Europe 39
7.3.1 Overview 39
7.4 APAC 41
7.4.1 Overview 41
7.5 Rest of the World 42
7.5.1 Overview 42
8 Competitive Landscape 44
9 Vendor Profiles 46
9.1 Novartis AG 46
9.1.1 Overview 46
9.1.2 Business Unit 51
9.1.3 Geographic Presence 51
9.1.4 Business Focus 52
9.1.5 SWOT Analysis 52
9.1.6 Business Strategy 53
9.2 Valeant Pharmaceuticals International Inc. 54
9.2.1 Overview 54
9.2.2 Business Unit 56
9.2.3 Geographic Presence 57
9.2.4 Business Focus 57
9.2.5 SWOT Analysis 58
9.2.6 Business Strategy 58
9.3 Teva Pharmaceutical Industries Ltd. 59
9.3.1 Overview 59
9.3.2 Business Unit 61
9.3.3 Geographic Presence 62
9.3.4 Business focus 63
9.3.5 SWOT analysis 63
9.3.6 Business Strategy 64
9.4 Akron Inc 64
9.4.1 Overview 64
9.4.2 Business Focus 67
9.4.3 SWOT Analysis 67
9.4.4 Business Strategy 68
10 Companies to Watch For 69
10.1 Santen Pharmaceutical Co., Ltd. 69
10.1.1 Overview 69
10.2 Perrigo Company plc 70
10.2.1 Overview 70
10.3 Merck & Co. 71
10.3.1 Overview 71
10.4 Pfizer Inc., 72
10.4.1 Overview 72
10.4.2 Highlights 74
10.5 Daiichi Sankyo, Inc. 74
10.5.1 Overview 74
10.5.2 Overview 75
10.6 Bayer AG 75
10.6.1 Overview 75
10.7 F. Hoffmann-La Roche 76
10.7.1 Overview 76


List Of Tables

TABLE 1 PATENT EXPIRATION OF RESPIRATORY DRUGS 28
 TABLE 2 BACTERIAL CONJUNCTIVITES DRUGS MARKET REVENUE BY DRUG CLASS, 2017–2024 ($MILLION) 32
 TABLE 3 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 37
 TABLE 4 POPULATION LIVING IN ENDEMIC AREAS OF TRACHOMA BY COUNTRY 42
 TABLE 5 NOVARTIS AG: OFFERINGS 46
 TABLE 6 NOVARTIS AG: RECENT DEVELOPMENTS 47
 TABLE 7 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 54
 TABLE 8 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 54
 TABLE 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 59
 TABLE 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 59
 TABLE 11 AKORN INC: OFFERINGS 64
 TABLE 12 AKRON INC.: RECENT DEVELOPMENTS 65
 TABLE 13 SANTEN PHARMACEUTICAL CO., LTD.: OVERVIEW 69
 TABLE 14 SANTEN PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS 69
 TABLE 15 PERRIGO COMPANY PLC: OVERVIEW 70
 TABLE 16 PERRIGO COMPANY PLC: RECENT DEVELOPMENTS 70
 TABLE 17 MERCK & CO: OVERVIEW 71
 TABLE 18 MERCK & CO: RECENT DEVELOPMENTS 71
 TABLE 19 PFIZER: RECENT DEVELOPMENTS 73
 TABLE 20 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 74
 TABLE 21 BAYER AG: OVERVIEW 75
 TABLE 22 BAYER AG: RECENT DEVELOPMENTS 75
 TABLE 23 F. HOFFMANN-LA ROCHE: OVERVIEW 76
 TABLE 24 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 76
  


List Of Figures

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 9
CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 10
CHART 3 PHARMACEUTICAL DRUGS BY SALES, 2017 12
CHART 4 CAUSES OF SIGHT LOSS GLOBALLY 13
CHART 5 RESEARCH METHODOLOGY OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET 16
CHART 6 GLOBAL BACTERIAL CONJUCTIVITIS DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 19
CHART 7 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS 20
CHART 8 SEGMENTATION OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET 23
CHART 9 PORTER 5 FORCES OF BACTERIAL CONJUNCTIVITIS DRUGS MARKET 24
CHART 10 PEST ANALYSIS OF BACTERIAL CONJUNCTIVITIS DRUGS MARKET 25
CHART 11 MARKET DYNAMICS – DRO ANALYSIS 26
CHART 12 DRO – IMPACT ANALYSIS OF GLOBAL BACTERIAL CONJUCTIVITIS DRUGS MARKET 29
CHART 13 KEY STAKEHOLDERS 29
CHART 14 BACTERIAL CONJUNCTIVITES DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%) 31
CHART 15 FLUOROQUINOLONES DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 33
CHART 16 AMINOGLYCOSIDES DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 34
CHART 17 MACROLIDES DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 34
CHART 18 OTHER BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 35
CHART 19 BACTERIAL CONJUCNTIVITIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 37
CHART 20 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION) 38
CHART 21 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($MILLION) 40
CHART 22 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 ($MILLION) 41
CHART 23 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION) 42
CHART 24 NOVARTIS AG: OVERVIEW SNAPSHOT 46
CHART 25 NOVARTIS AG: BUSINESS UNITS 51
CHART 26 NOVARTIS AG: GEOGRAPHICAL PRESENCE 51
CHART 27 NOVARTIS AG: SWOT ANALYSIS 52
CHART 28 VALEANT PHARMACEUTICALS INTERNATIONAL INC: OVERVIEW SNAPSHOT 55
CHART 29 VALEANT PHARMACEUTICALS INTERNATIONAL INC: BUSINESS UNITS 56
CHART 30 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 57
CHART 31 VALEANT PHARMACEUTICALS INTERNATIONAL INC: SWOT ANALYSIS 58
CHART 32 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 60
CHART 33 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 61
CHART 34 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 62
CHART 35 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 63
CHART 36 AKRON INC: OVERVIEW SNAPSHOT 65
CHART 37 AKRON INC.: BUSINESS UNITS 67
CHART 38 AKRON INC.: SWOT ANALYSIS 67


Global Cupric Sulfate Market Research Report 2018

Cupric Sulfate Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the

USD 2850View Report

Global Photocatalyst Anion Light Market Research Report 2018

Photocatalyst Anion Light Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on

USD 2850View Report

Global Conjunctivitis Market Research Report 2018

Conjunctivitis Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main

USD 2850View Report

Global Bacterial Conjunctivitis Drugs Industry Market Research Report

The Bacterial Conjunctivitis Drugs market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR

USD 2960View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2750
  • Site Licence    USD 3500
  • Global Licence    USD 4500
$ 2750

Reports Details

Published Date : Jun 2018
No. of Pages :82
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Infoholic Research
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube